Novo Nordisk stops development of new insulin product
A phase I trial turned out to be the nail in the coffin for Novo Nordisk’s potential treatment combining a basal insulin with a cholesterol lowering substance.
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen
Novo Nordisk has terminated the development of what could have ended up being a new insulin product, insulin 147, according to the Danish pharmaceutical firm’s financial report on Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Disappointing phase I results halt Novo's Dutch acquisition
For subscribers
